Combating Generics: Pharmaceutical Brand Defense for 2007 (PH76)

Maximize drug revenues by preparing for patent expiry and generic competition early in product lifecycles.

Generic drugs now account for more than 50% of all prescriptions filled in the US and more than $40 billion in prescription sales worldwide. More than $80 billion worth of global blockbuster drugs face US patent expiration by 2008.

Use this report to better understand and act on the range of options available to branded companies defending products against generic threats. The information contained within is gathered from individuals involved in product lifecycle management, brand management and marketing, portfolio management, market research, and other functions associated with long-term brand viability.

Findings integrate primary and secondary information to present readers with a comprehensive look at current generics defense efforts, including the following strategies:

Defensive pricing

Increased marketing and promotion

Approval for additional indications

Next-generation product launches

Patent litigation

Authorized generics and corporate generics subsidiaries

Pediatric extensions

Rx-to-OTC switching

Measure resource levels against other companies' budgets and staffing support for anti-generics efforts, and review case studies of anti-generic battles, discussions of legal and regulatory developments, and profiles of leading generics manufacturers.

Published 2006

265 Pages

300+ Metrics

80+ Charts and Diagrams

Format: PDF
Table of Contents
Price: $3,995.00 / GBP1,997.50